Raseglurant
Appearance
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H13FN2 |
Molar mass | 240.281 g·mol−1 |
3D model (JSmol) | |
| |
|
Raseglurant (INN) (code name ADX-10059) is a negative allosteric modulator of the mGlu5 receptor and derivative of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety.[1][2][3] It reached phase II clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use.[3][4][5]
See also
References
- ^ Annual Reports in Medicinal Chemistry. Academic Press. 31 December 2012. pp. 80–. ISBN 978-0-12-397214-9.
- ^ "Don't Dodge the Dentist – Tips for Dealing with Dental Anxiety". Retrieved 2017-04-05.
- ^ a b Murray B. Stein; Thomas Steckler (30 July 2010). Behavioral Neurobiology of Anxiety and Its Treatment. Springer Science & Business Media. pp. 397–. ISBN 978-3-642-02912-7.
- ^ Celia Dominguez (18 November 2010). Neurodegenerative Diseases. Springer Science & Business Media. pp. 120–. ISBN 978-3-642-16758-4.
- ^ Nicholas J. Shaheen (25 March 2013). Benign and Neoplastic Conditions of the Esophagus, An Issue of Gastroenterology Clinics,. Elsevier Health Sciences. pp. 119–. ISBN 1-4557-7175-9.
External links